TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Telomir Pharmaceuticals, Inc. ( (TELO) ) has shared an update.
On October 6, 2025, Telomir Pharmaceuticals announced promising preclinical findings for its investigational compound, Telomir-1, in aggressive prostate cancer models. The studies revealed that Telomir-1 can reset abnormal DNA methylation, reactivating tumor suppressor genes MASPIN and RASSF1A, which are crucial in blocking tumor invasion and improving chemotherapy responsiveness. These findings suggest that Telomir-1 may effectively counteract chemotherapy-induced resistance and limit metastasis, offering potential advancements in cancer treatment. The company is advancing Telomir-1 with IND-enabling studies.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing innovative treatments for cancer. The company is particularly involved in creating compounds that address significant challenges in oncology, such as metastasis and treatment resistance.
Average Trading Volume: 4,520,762
Technical Sentiment Signal: Sell
Current Market Cap: $45.19M
For detailed information about TELO stock, go to TipRanks’ Stock Analysis page.